Intersect Capital’s Biogen BIIB Stock Holding History

Intersect Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$208K	Buy	1,021 +29	+3%	+$5.93K	0.06%	316
2022 Q1	$209K	Buy	+992	New	+$216K	0.04%	408
2021 Q4	–	Sell	-1,842	Closed	-$521K	–	431
2021 Q3	$521K	Buy	1,842 +3	+0.2%	+$983	0.09%	183
2021 Q2	$637K	Buy	1,839 +375	+26%	+$114K	0.11%	149
2021 Q1	$410K	Buy	1,464 +271	+23%	+$73.1K	0.08%	196
2020 Q4	$292K	Buy	+1,193	New	+$308K	0.06%	217
2015 Q2	–	Sell	-8	Closed	-$3K	–	141
2015 Q1	$3K	Sell	8 -12	-60%	-$4.73K	﹤0.01%	396
2014 Q4	$7K	Buy	+20	New	+$6.47K	0.01%	366

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Intersect Capital's BIIB Position: Q2 2022 in Review

Intersect Capital increased its Biogen (BIIB) stake by 2.9% in Q2 2022, buying an estimated $5.93K and bringing the position to 1,021 shares worth $208K. The position accounts for 0.06% of the portfolio, ranked #316.

Intersect Capital first reported a position in BIIB in Q4 2014 and has held it in 8 quarters since. The position peaked at $637K in Q2 2021. 928 funds tracked by Wall St. Rank hold BIIB as of Q2 2022.

Intersect Capital held 1,021 shares of Biogen worth $208K as of Q2 2022.
Intersect Capital bought 29 Biogen shares in Q2 2022, an estimated $5.93K.
Biogen made up 0.06% of Intersect Capital's portfolio in Q2 2022, its #316 holding.
Intersect Capital first reported a position in Biogen in Q4 2014 and has held it in 8 quarters since.
Intersect Capital's Biogen position peaked at $637K in Q2 2021.
928 funds tracked by Wall St. Rank held Biogen as of Q2 2022.

Based on Intersect Capital's 13F filing for Q2 2022, filed 2 Sep 2022.